Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.

نویسندگان

  • Sarah I Jawed
  • Klaus Busam
  • Xuan Wang
  • Steven Horwitz
  • Christiane Querfeld
چکیده

Approximately20%ofpatientspresentwithatypicalorvariant formsof PR,which are less readily recognized than typical eruptions and may pose a diagnostic challenge.2,3 The morphologic characteristics of the eruption may be papular, vesicular, purpuric or hemorrhagic, or urticarial. Very small lesions will be observed in papular PR, and PR with enormous plaques is known as pityriasis rosea gigantea of Darier. Amorphologic variant characterized by atypical large patches that tend to be few in number and coalescent has been described. In this variant, commonly referred to as pityriasis circinata et marginataofVidalor limb-girdlePR, theeruptiongenerally appears in the axillae, the groin, or both, with the trunk and extremities usually spared.4,5 A simple classification for atypical pityriasis rosea has been proposed by Chuh and Zawar (Box).6 In our patient, the eruption fulfills all 3 essential clinical features (discrete annular lesions, scaling, andperipheral collarette scaling with central clearance on at least 2 lesions), all 3 optional clinical features (relative truncal distribution, orientationalongskincleavage lines, andheraldpatch), andnone of the exclusional clinical features. This case has clinical featuresof localizedPR,papularPR,andpityriasiscircinataetmarginata of Vidal. It should also be noted that the involvement of penile and scrotal skin is rarely reported in PR. Physicians should be aware of the wide spectrum of PR variants so that appropriate management and reassurance can be offered.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Alemtuzumab in refractory Sézary syndrome*

Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refrac...

متن کامل

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.

We present the results of an open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) (erythrodermic mycosis fungoides and Sézary syndrome). Ten patients received alemtuzumab intravenously using an escalating dose regimen with a final dose of 30 mg three times weekly for 4 weeks followed by subc...

متن کامل

Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.

Alemtuzumab is a monoclonal antibody that has been used to treat refractory cases of Sézary syndrome (SS) and advanced mycosis fungoides. We present 5 patients with SS who were treated with alemtuzumab between 2008 and 2012, with an overall response rate of 80% (40% partial response and 40% complete response). A regimen of 10mg administered subcutaneously was well tolerated with acceptable toxi...

متن کامل

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.

Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sézary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) t...

متن کامل

A mouse model for the Sézary syndrome

BACKGROUND The Sézary syndrome is an aggressive leukemic form of cutaneous T cell lymphoma and there is no cure of this disease. Until now there is no true animal model for Sézary syndrome, by which new drugs against the disease could be tested. METHODS Immune deficient CB-17 SCID beige mice were injected subcutaneously with HUT78 cells, a cell line, derived from a Sézary syndrome patient. De...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • JAMA dermatology

دوره 150 9  شماره 

صفحات  -

تاریخ انتشار 2014